This milestone marks a breakthrough after unsuccessful attempts to develop painkillers without the addictive potential of ...
The drug, shown to be almost as effective as opioids for short-term pain, is the first fundamentally new kind of painkiller ...
Journavx is the first and only approved non-opioid oral painkiller and the first new class of pain medicine approved in more ...
Vertex Pharmaceuticals (VRTX – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Terence ...
The drug, Journavx by Vertex Pharmaceuticals, blocks pain signals to the brain, making it nonaddictive. The Food and Drug ...
On Thursday, in a major step forward in pain management, the U.S. Food and Drug Administration has approved a new nonopioid ...
FDA approves Journavx, a non-opioid medication for moderate to severe acute pain. Learn about its efficacy and side effects.
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the U.S. Food and Drug Administration (FDA) has ...
Vertex Pharmaceuticals on Thursday won approval from the Food and Drug Administration for a non-opioid pain drug, clearing ...
Despite high demand for an option like Journavx, doctors fear the drug’s price could be a major hangup for insurers, ...
The FDA has approved Vertex Pharmaceuticals’ oral Journavx (suzetrigine) to treat adults with moderate-to-severe acute pain.
The FDA has approved Journavx, a new non-opioid pain medication designed to reduce addiction and overdose risks.